<p>美银证券发布报告称，百济神州（06160.HK）+1.100 (+0.610%) 空头头寸为 5562 万美元；比例为 15.363%。2 月份在中国的样本药品总销售额为人民币 6.024 亿元，同比增长 17.7%。自研和引进产品的销售额分别达到人民币 3.322 亿元和人民币 2.698 亿元，分别同比增长 20.3% 和 14.5%。其中，2 月份的替雷利珠单抗和扎努布单抗的销售额分别为人民币 2.447 亿元和人民币 8730 万元，同比增长 14.1% 和 42.6%。该券商维持 “买入” 评级，给予百济神州（ONC.US）美国股票目标价为 403.8 美元，香港股票目标价为 243.83 港元。+1.100 (+0.610%) 空头头寸为 5562 万美元；比例为 15.363%。（ha/w）（香港股票报价延迟至少 15 分钟。空头数据截至 2026-04-27 16:25。）（实时流式美国股票报价；除所有场外交易报价外，均至少延迟 15 分钟。）</p>
<p>本文由 AI 自动翻译，中文版本应视为权威版本。AASTOCKS.com Limited 不保证其准确性或完整性，并对因使用此翻译而产生的任何损害或损失不承担任何责任。</p>

百济神州

鹏华上证科创板生物医药ETF

博时恒生港股通创新药精选ETF

华宝恒生港股通创新药精选ETF

易方达恒生港股通创新药ETF

<p>BofAS 对百济神州维持买入评级，目标价为 243.83 港元。该公司在中国的药品总销售额在 2 月份为 6.024 亿元人民币，同比增长 17.7%。自研和引进产品的销售额分别为 3.322 亿元人民币和 2.698 亿元人民币，同比增长 20.3% 和 14.5%。值得注意的是，替雷利珠单抗和扎努布单抗的销售额分别达到 2.447 亿元人民币和 8730 万元人民币，同比增长 14.1% 和 42.6%</p>

<p>BofAS issued a report stating that BEIGENE (06160.HK) +1.100 (+0.610%)  Short selling $55.62M; Ratio 15.363%  recorded total sample drug sales in China of RMB602.4 million in February, up 17.7% YoY. Sales of self-developed and in-licensed products reached RMB332.2 million and RMB269.8 million, rising 20.3% YoY and 14.5% YoY, respectively. Among them, sales of tislelizumab and zanubrutinib in February were RMB244.7 million and RMB87.3 million, representing YoY growth of 14.1% and 42.6%, respectively. The broker maintained its Buy rating, with a US stock TP of USD403.8 for BEIGENE (ONC.US) and a Hong Kong stock TP of HKD243.83 for BEIGENE (06160.HK) +1.100 (+0.610%)  Short selling $55.62M; Ratio 15.363%  . (ha/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-27 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)</p>
<div class="lb-trans"><p>美银证券发布报告称，百济神州（06160.HK）+1.100 (+0.610%) 空头头寸为 5562 万美元；比例为 15.363%。2 月份在中国的样本药品总销售额为人民币 6.024 亿元，同比增长 17.7%。自研和引进产品的销售额分别达到人民币 3.322 亿元和人民币 2.698 亿元，分别同比增长 20.3% 和 14.5%。其中，2 月份的替雷利珠单抗和扎努布单抗的销售额分别为人民币 2.447 亿元和人民币 8730 万元，同比增长 14.1% 和 42.6%。该券商维持 “买入” 评级，给予百济神州（ONC.US）美国股票目标价为 403.8 美元，香港股票目标价为 243.83 港元。+1.100 (+0.610%) 空头头寸为 5562 万美元；比例为 15.363%。（ha/w）（香港股票报价延迟至少 15 分钟。空头数据截至 2026-04-27 16:25。）（实时流式美国股票报价；除所有场外交易报价外，均至少延迟 15 分钟。）</p>
</div><p>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</p>
<div class="lb-trans"><p>本文由 AI 自动翻译，中文版本应视为权威版本。AASTOCKS.com Limited 不保证其准确性或完整性，并对因使用此翻译而产生的任何损害或损失不承担任何责任。</p>
</div>

BofAS Maintains Buy on BEIGENE  with TP at HKD243.83

AASTOCKS News

美国银行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

美银证券维持对百济神州的买入评级，目标价定为 243.83 港元